Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 1996 clinical trials
featured
Small cell lung cancer (SCLC) Receiving Zepzelca

People with SMALL CELL LUNG CANCER are asked to participate in a research study being conducted by Montefiore Medical Center.

lung carcinoma
  • 0 views
  • 06 Aug, 2021
  • 1 location
featured
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

lung cancer
cancer
lung carcinoma
  • 92 views
  • 23 Nov, 2020
  • 1 location
featured
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) (Alliance A151216)

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) (Alliance A151216)

lung cancer
cancer
lung carcinoma
  • 72 views
  • 03 Dec, 2020
  • 1 location
featured
MS200647-0005: A Multicenter, Double Blind, Randomized, Controlled Study of M7824 with Concurrent Chemoradiation Followed by M7824 versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants with Unresectable Stage III Non-small Cell Lung Cancer

The main purpose of this study is to evaluate safety and efficacy in participants treated with concomitant chemoradiation therapy (cCRT) plus M7824 followed by M7824 compared to cCRT plus placebo followed by durvalumab.

  • 0 views
  • 31 Mar, 2021
  • 1 location
featured
  • 432 views
  • 23 Nov, 2020
  • 1 location
featured
A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK

crizotinib
lung cancer
lung carcinoma
  • 98 views
  • 23 Nov, 2020
  • 1 location
featured
Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

lung cancer
epidermal growth factor receptor
EGFR
lung carcinoma
growth factor
  • 100 views
  • 23 Nov, 2020
  • 1 location
featured
  • 182 views
  • 23 Nov, 2020
  • 1 location
featured
A Study of Nivolumab plus Ipilimumab in Combination with Chemotherapy vs Chemotherapy alone as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC)

A Study of Nivolumab plus Ipilimumab in Combination with Chemotherapy vs Chemotherapy alone as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC)

systemic therapy
non-small cell carcinoma
lung carcinoma
nivolumab
stage iv non-small cell lung cancer
  • 640 views
  • 24 Nov, 2020
  • 1 location
featured
QUILT -2.023: A phase 2, open-label, randomized study of ALT-803 in combination with pembrolizumab vs pembrolizumab alone as first-line treatment for patients with metastatic NSCLC

This is a phase 2, open-label, randomized study to compare the safety and efficacy of combination therapy with ALT-803 and pembrolizumab (experimental arm) versus pembrolizumab alone (control arm), as first-line treatment for subjects with metastatic NSCLC in which pembrolizumab is indicated for first-line treatment.

  • 2 views
  • 31 Mar, 2021
  • 1 location